AR073800A1 - Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196 - Google Patents
Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196Info
- Publication number
- AR073800A1 AR073800A1 ARP090103885A ARP090103885A AR073800A1 AR 073800 A1 AR073800 A1 AR 073800A1 AR P090103885 A ARP090103885 A AR P090103885A AR P090103885 A ARP090103885 A AR P090103885A AR 073800 A1 AR073800 A1 AR 073800A1
- Authority
- AR
- Argentina
- Prior art keywords
- mirna
- expression
- hcv
- bach
- hmox1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente solicitud se refiere a métodos de tratamiento de células infectadas con VHC y de mamíferos que padecen la infeccion con el VHC mediante la transfeccion de las células infectadas con mímico miRNA-196. El mímico miRNA-196 disminuye significativamente la expresion de la proteína Bach 1 el gen del VHC, en tanto aumenta además la expresion del gen HMOX1. miRNA-196 se une al 3'-UTR del mRNA de Bach 1 para reducirla expresion de Bach 1. Como tal, el miRNA-196 puede jugar un papel importante en la regulacion de la replicacion del VHC y la expresion de HMOX1/Bach 1 en los hepatocitos. La presente solicitud además provee una formulacion para el tratamiento de células que expresan el VHC que comprende una cantidad terapéuticamente efectiva de miRNA-196 de modo que disminuya la expresion de Bach 1 y el gen del VHC incrementando a la par la expresion de HMOX1. Las formulaciones están adaptadas para permitir la transfeccion del mímico miRNA-196 en hepatocitos que expresan proteínas del VHC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10360908P | 2008-10-08 | 2008-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073800A1 true AR073800A1 (es) | 2010-12-01 |
Family
ID=41559924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103885A AR073800A1 (es) | 2008-10-08 | 2009-10-08 | Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2352829A1 (es) |
JP (1) | JP2012505233A (es) |
KR (1) | KR20110065568A (es) |
CN (1) | CN102257140A (es) |
AR (1) | AR073800A1 (es) |
AU (1) | AU2009302344A1 (es) |
BR (1) | BRPI0914060A2 (es) |
CA (1) | CA2739948A1 (es) |
MX (1) | MX2011003813A (es) |
WO (1) | WO2010042683A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059638A1 (en) | 2011-10-21 | 2013-04-25 | Abbvie Inc. | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
CN103826627B (zh) | 2011-10-21 | 2016-02-24 | 艾伯维公司 | 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途 |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
CN110724734B (zh) * | 2019-10-22 | 2020-06-16 | 北京恩泽康泰生物科技有限公司 | 含miRNA mimic的人造脂质体及其制备方法与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
US8415323B2 (en) * | 2007-08-27 | 2013-04-09 | The Regents Of The University Of California | MicroRNAs for inhibiting viral replication |
-
2009
- 2009-10-08 EP EP09741517A patent/EP2352829A1/en not_active Withdrawn
- 2009-10-08 WO PCT/US2009/059944 patent/WO2010042683A1/en active Application Filing
- 2009-10-08 AU AU2009302344A patent/AU2009302344A1/en not_active Abandoned
- 2009-10-08 BR BRPI0914060A patent/BRPI0914060A2/pt not_active IP Right Cessation
- 2009-10-08 JP JP2011531164A patent/JP2012505233A/ja not_active Withdrawn
- 2009-10-08 MX MX2011003813A patent/MX2011003813A/es not_active Application Discontinuation
- 2009-10-08 CA CA2739948A patent/CA2739948A1/en not_active Abandoned
- 2009-10-08 KR KR1020117010438A patent/KR20110065568A/ko not_active Application Discontinuation
- 2009-10-08 CN CN2009801451621A patent/CN102257140A/zh active Pending
- 2009-10-08 AR ARP090103885A patent/AR073800A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20110065568A (ko) | 2011-06-15 |
WO2010042683A1 (en) | 2010-04-15 |
JP2012505233A (ja) | 2012-03-01 |
CN102257140A (zh) | 2011-11-23 |
EP2352829A1 (en) | 2011-08-10 |
AU2009302344A2 (en) | 2011-04-28 |
CA2739948A1 (en) | 2010-04-15 |
MX2011003813A (es) | 2011-07-28 |
BRPI0914060A2 (pt) | 2015-11-17 |
AU2009302344A1 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qian et al. | Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection | |
AR073800A1 (es) | Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196 | |
MX2020011805A (es) | Agentes de iarn para infeccion causada por el virus de la hepatitis b. | |
CY1119765T1 (el) | Ιοσωματιδια αδενο-συσχετιζομενου ιου με καψιδιο παραλλαγματος και μεθοδοι χρησης εξ' αυτων | |
Parashar et al. | Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus | |
Li et al. | Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis | |
Wen et al. | Cellular microRNA-miR-548g-3p modulates the replication of dengue virus | |
BRPI0714495B8 (pt) | lentivírus deficiente para replicação recombinante pseudotipado | |
Moschos et al. | Cell-penetrating-peptide-mediated siRNA lung delivery | |
CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
Han et al. | Delivery of anti-miRNA-221 for colorectal carcinoma therapy using modified cord blood mesenchymal stem cells-derived exosomes | |
Hacke et al. | Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity | |
Hansson et al. | Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells | |
Park et al. | Inhibition of hepatitis B virus replication by ligand-mediated activation of RNase L | |
Oh et al. | Anti-viral activities of umbilical cord mesenchymal stem cell-derived small extracellular vesicles against human respiratory viruses | |
Chen et al. | Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy | |
El Hidan et al. | Scorpion‐Derived Antiviral Peptides with a Special Focus on Medically Important Viruses: An Update | |
Yang et al. | Nesprin-1 plays an important role in the proliferation and apoptosis of mesenchymal stem cells | |
Chen et al. | Ago-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi | |
Elinger | HBV: stowaway of NTCP | |
Porntrakulpipat et al. | RNA interference targeting nucleocapsid protein (C) inhibits classical swine fever virus replication in SK-6 cells | |
Pan et al. | Panax notoginseng saponins ameliorates coxsackievirus B3-induced myocarditis by activating the cystathionine-γ-lyase/hydrogen sulfide pathway | |
He et al. | High reduced/oxidized glutathione ratio in infectious spleen and kidney necrosis virus-infected cells contributes to degradation of VP08R multimers | |
CN109971761B (zh) | 脂肪酸结合蛋白4的小干扰rna及其应用 | |
Ding et al. | The program of antiviral agents inhibits virus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |